Toward a More Rational Policy for Autologous Hematopoietic Stem Cell Mobilization

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 10, 2012, Pages 1468-1470

  Devine, Steven M ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; LENALIDOMIDE; PLERIXAFOR;

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CD34 SELECTION; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; HEALTH CARE POLICY; HUMAN; NOTE;

ANTIGENS, CD34; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG COMBINATIONS; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HETEROCYCLIC COMPOUNDS; HUMANS; IMMUNOLOGIC FACTORS; LYMPHOMA, NON-HODGKIN; MULTIPLE MYELOMA; RECEPTORS, CXCR4; TRANSPLANTATION, AUTOLOGOUS;

EID: 84866168742     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2012.08.001     Document Type: Note

References (13)

1. DiPersio J.F., Micallef I.N., Stiff P.J., et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol 2009, 27:4767-4773.
2. DiPersio J.F., Stadtmauer E.A., Nademanee A., et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009, 113:5720-5726.
3. Costa L.J., Abbas J., Hogan K.R., et al. Growth factor plus preemptive ('just-in-time') plerixafor successfully mobilizes hematopoietic stem cells in multiple myeloma patients despite prior lenalidomide exposure. Bone Marrow Transplant 2012, [Epub ahead of print].
4. Costa L.J., Alexander E.T., Hogan K.R., et al. Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization. Bone Marrow Transplant 2011, 46:64-69.
5. Micallef I.N., Ho A.D., Klein L.M., et al. Plerixafor (Mozobil) for stem cell mobilization in patients with multiple myeloma previously treated with lenalidomide. Bone Marrow Transplant 2011, 46:350-355.
6. Micallef I.N., Jacobsen E.D., Shaughnessy P., et al. G-CSF plus plerixafor (Mozobil) to mobilize hematopoietic stem cells in patients with thrombocytopenia or leukopenia prior to auto-SCT. Bone Marrow Transplant 2012, [Epub ahead of print].
7. Shaughnessy P., Islas-Ohlmayer M., Murphy J., et al. Cost and clinical analysis of autologous hematopoietic stem cell mobilization with G-CSF and plerixafor compared to G-CSF and cyclophosphamide. Biol Blood Marrow Transplant 2011, 17:729-736.
8. Stiff P., Micallef I., McCarthy P., et al. Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient. Biol Blood Marrow Transplant 2009, 15:249-256.
9. Nademanee A.P., DiPersio J.F., Maziarz R.T., et al. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34+ hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34+ cell count: results of a subset analysis of a randomized trial. Biol Blood Marrow Transplant 2012, 18:1564-1572.
10. Stiff P.J., Micallef I., Nademanee A.P., et al. Transplanted CD34(+) cell dose is associated with long-term platelet count recovery following autologous peripheral blood stem cell transplant in patients with non-Hodgkin lymphoma or multiple myeloma. Biol Blood Marrow Transplant 2011, 17:1146-1153.
11. McCarthy P.L., Owzar K., Hofmeister C.C., et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 2012, 366:1770-1781.
12. Bolwell B.J., Pohlman B., Rybicki L., et al. Patients mobilizing large numbers of CD34+ cells ('super mobilizers') have improved survival in autologous stem cell transplantation for lymphoid malignancies. Bone Marrow Transplant 2007, 40:437-441.
13. Costa L.J., Miller A.N., Alexander E.T., et al. Growth factor and patient-adapted use of plerixafor is superior to CY and growth factor for autologous hematopoietic stem cells mobilization. Bone Marrow Transplant 2011, 46:523-528.